Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Latest Ras subfamily Stories

2014-04-08 12:07:17

-NRAS is one of the most studied cancer-related genes. -This study found that the gene produces five variants, not just one form as thought. -The finding might help improve drugs for cancers that involve NRAS. A new study shows that a gene discovered 30 years ago and now known to play a fundamental role in cancer development produces five different gene variants (called isoforms), rather than just the one original form, as thought. The study of the NRAS gene by researchers at The Ohio...

2014-03-17 08:29:15

Company leveraging the scalability of its proprietary platform and next generation sequencing to introduce a full line of multiplexed urine-based oncogene mutation assays with superb sensitivity SAN DIEGO, March 17, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it has released its first multiplexed oncogene mutation assay, integrating the Company's proprietary sample preparation and primer technologies with...

2014-01-29 23:32:09

Introducing CE-IVD marked kits with expanded mutation coverage in colorectal cancer for Kras, Nras, and Braf genes. Tarzana, Calif (PRWEB) January 29, 2014 Today EntroGen (http://www.entrogen.com) announced immediate availability of its expanded colorectal cancer screening products. EntroGen K-Ras and N-Ras Mutation Analysis kits have been updated to include coverage for exon 2, 3 and 4 mutations in both genes. The Company has obtained a CE-IVD mark for these products. The importance of...

2014-01-21 23:00:43

ACA is Changing How Some Businesses Can Use HRAs in 2014 Park City, Utah (PRWEB) January 21, 2014 Today, Zane Benefits, the #1 Online Health Benefits Solution, published new information on HRAs and 2014. According to Zane Benefits’ website, health reform is bringing sweeping changes to the health insurance industry, including how employers can use Health Reimbursement Arrangements (HRAs). Zane Benefits outlines what employers need to know about the use of HRAs in 2014. #1) Integrated...

2014-01-07 14:18:21

Why inhibition of both pathways is important In the study by Toulany et al., it was demonstrated for the first time that long term treatment with inhibitors of PI3K (as it is performed clinically) results in a reactivation of the major survival component Akt through a so far unknown regulatory loop via ERK1/2. This reactivation of Akt limits quite efficiently the response of the tested tumor cell lines presenting constitutively active K-Ras activity (both through K-RAS mutation or...

2013-12-02 21:15:20

Scientists have described a new family of proteins that appear to play a key role in cancer and might be targets for future cancer drugs. A major new study in the journal Nature sets out the structure of the new family, called glutamate intramembrane proteases – the founding member of which plays a critical role in transforming healthy cells into cancer cells. The research, funded by Cancer Research UK and conducted by scientists at The Institute of Cancer Research, London, defined...

2013-11-20 12:25:48

Groundbreaking Research Offers Potential to Develop Therapies To Treat An Important Genetic Lesion in Human Cancer LA JOLLA, Calif., Nov. 20, 2013 /PRNewswire/ -- Wellspring Biosciences, a leading biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of cancer, announced today a publication from Kevan Shokat, Ph.D., one of its founders and chairman of its scientific advisory board, in the journal Nature that describes the discovery of...

2013-11-12 23:19:49

Despite recent regulations, stand-alone HRAs are still a go for one-person plan Park City, Utah (PRWEB) November 12, 2013 Today, Zane Benefits, the number one online small business health benefits solution, published new information on HRAs for one person. According to Zane Benefits’ website, for over a decade, Health Reimbursement Arrangements (HRAs) have been widely used by small business owners and one-person non-profits as a way to increase their tax savings and to receive tax-free...

2013-10-21 10:08:34

Patients with cancers driven by the protein KRAS, which are particularly hard to treat, may benefit from small molecules that attach to and disrupt the function of a KRAS-containing protein complex, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23. Mutant forms of the protein KRAS are found in approximately 30 percent of all cancers. They are responsible for many of the hallmarks of these...

2013-09-11 16:24:27

Study Links RAS Mutations to Vectibix Clinical Response in Patients With Metastatic Colorectal Cancer THOUSAND OAKS, Calif., Sept. 11, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the publication of a biomarker analysis of Vectibix(®) (panitumumab) in combination with FOLFOX, a type of oxaliplatin-based chemotherapy, for the first-line treatment of patients with metastatic colorectal cancer (mCRC). Published in the New England Journal of Medicine, the analysis found that...